• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

德国皮肤科、胃肠病学和风湿病学实践中生物药物的治疗线

Lines of therapy with biological drugs in dermatology, gastroenterology, and rheumatology practices in Germany
.

作者信息

Kostev Karel, Bauer Anna, Jacob Louis

出版信息

Int J Clin Pharmacol Ther. 2019 Apr;57(4):182-187. doi: 10.5414/CP203371.

DOI:10.5414/CP203371
PMID:30738498
Abstract

OBJECTIVE

The goal of the present study was to investigate lines of therapy with biological drugs in patients followed in dermatology, gastroenterology, and rheumatology practices in Germany.

MATERIALS AND METHODS

The study included patients aged 18 years or over who had received a biological therapy in dermatology, gastroenterology, or rheumatology practices in Germany in 2017 (index date). The primary outcome of the study was the prevalence of different lines of therapy (first-, second-, third-, and at least fourth-line therapies) by type of practice, age, and gender. The second outcome was the association between basic characteristics (type of practice, age, and gender) and lines of therapy with biological drugs.

RESULTS

The present study included 27,816 individuals. The mean age (SD) at index date was 50.7 years (15.4 years). Biological drugs were prescribed as first-line therapies in 60% of patients (dermatology 73%, gastroenterology 61%, and rheumatology 56%). The prevalence of first-line therapies ranged from 57% in individuals aged 41 - 50 years to 65% in those aged 18 - 30 years. Furthermore, 56% of women and 61% of men were prescribed biological drugs as first-line therapies. Finally, the likelihood of being prescribed biological drugs as second-, third-, or at least fourth-line therapies was significantly associated with being followed in a rheumatology or gastroenterology practice, older age, and female gender.

CONCLUSION: Biological drugs were prescribed as first-line therapies in most cases. The type of practice as well as the patient's age and gender had a significant impact on lines of therapy with biological drugs.
.

摘要

目的

本研究的目的是调查德国皮肤科、胃肠病科和风湿病科门诊中使用生物药物的治疗方案。

材料与方法

该研究纳入了2017年(索引日期)在德国皮肤科、胃肠病科或风湿病科门诊接受过生物治疗的18岁及以上患者。该研究的主要结局是按科室类型、年龄和性别划分的不同治疗方案(一线、二线、三线和至少四线治疗)的患病率。第二个结局是基本特征(科室类型、年龄和性别)与生物药物治疗方案之间的关联。

结果

本研究共纳入27,816名个体。索引日期时的平均年龄(标准差)为50.7岁(15.4岁)。60%的患者接受生物药物作为一线治疗(皮肤科73%,胃肠病科61%,风湿病科56%)。一线治疗的患病率在41 - 50岁个体中为57%,在18 - 30岁个体中为65%。此外,56%的女性和61%的男性接受生物药物作为一线治疗。最后,接受二线、三线或至少四线生物药物治疗的可能性与在风湿病科或胃肠病科门诊就诊、年龄较大以及女性性别显著相关。

结论

大多数情况下生物药物被用作一线治疗。科室类型以及患者的年龄和性别对生物药物治疗方案有显著影响。

相似文献

1
Lines of therapy with biological drugs in dermatology, gastroenterology, and rheumatology practices in Germany
.德国皮肤科、胃肠病学和风湿病学实践中生物药物的治疗线
Int J Clin Pharmacol Ther. 2019 Apr;57(4):182-187. doi: 10.5414/CP203371.
2
Persistence with biological drugs in psoriasis patients followed in dermatology practices in Germany: A retrospective cohort study of 1,201 patients
.德国皮肤科诊所随访的银屑病患者生物制剂持续使用情况:一项对1201例患者的回顾性队列研究
Int J Clin Pharmacol Ther. 2020 Feb;58(2):74-81. doi: 10.5414/CP203612.
3
[Treatment of psoriasis with biologics: a survey of dermatological and rheumatological practice at Reims University Hospital].[生物制剂治疗银屑病:兰斯大学医院皮肤科和风湿病科实践调查]
Ann Dermatol Venereol. 2012 May;139(5):355-62. doi: 10.1016/j.annder.2012.03.005. Epub 2012 Apr 21.
4
[Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].[炎症医学中生物制剂的演变——胃肠病学、风湿病学和皮肤病学中的生物类似药]
Dtsch Med Wochenschr. 2014 Nov;139(47):2399-404. doi: 10.1055/s-0034-1387371. Epub 2014 Nov 12.
5
Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit.
Reumatol Clin (Engl Ed). 2019 Mar-Apr;15(2):63-68. doi: 10.1016/j.reuma.2018.11.008. Epub 2019 Jan 26.
6
Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis.德国风湿病科医生诊所中类风湿关节炎患者使用生物药物的二线治疗:一项回顾性数据库分析。
Rheumatol Int. 2016 Aug;36(8):1113-8. doi: 10.1007/s00296-016-3448-9. Epub 2016 Mar 2.
7
Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs.德国成年局灶性癫痫患者的真实药物治疗模式:对近期获批抗癫痫药物的纵向和横断面分析
Ger Med Sci. 2017 Jun 12;15:Doc09. doi: 10.3205/000250. eCollection 2017.
8
Preparing for subsequent entry biologics in dermatology and rheumatology in Canada.在加拿大为随后进入皮肤科和风湿病学的生物制剂做准备。
J Cutan Med Surg. 2013 Sep-Oct;17(5):340-6. doi: 10.2310/7750.2013.13006.
9
Seminars in research 2013: joint experiences using biologics in rheumatology and dermatology.2013年研究研讨会:风湿病学和皮肤病学中使用生物制剂的联合经验
Drug Dev Res. 2014 Nov;75 Suppl 1:S1-2. doi: 10.1002/ddr.21217.
10
The Influence of Polypharmacy on the Initiation of Anti-Dementia Therapy in Germany.德国多药治疗对启动抗痴呆症治疗的影响。
J Alzheimers Dis. 2018;64(3):827-833. doi: 10.3233/JAD-180382.

引用本文的文献

1
Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease-A Single Center Case-Control Study.预处理不影响炎症性肠病儿科患者英夫利昔单抗输注反应的发生率——一项单中心病例对照研究
J Clin Med. 2021 Jul 19;10(14):3177. doi: 10.3390/jcm10143177.